News

Lose weight with a combination of behavioral therapy and diabetes medication

Lose weight with a combination of behavioral therapy and diabetes medication


We are searching data for your request:

Forums and discussions:
Manuals and reference books:
Data from registers:
Wait the end of the search in all databases.
Upon completion, a link will appear to access the found materials.

New Approach to Overweight and Obesity Control?

Intensive behavioral therapy in combination with the use of the drug liraglutide 3.0 mg can lead to significant weight loss in humans. This finding could help fight obesity and obesity in society in the future.

A recent study by the University of Pennsylvania at Philadelphia found that a combination of behavioral therapy and liraglutide 3.0 mg appeared to support weight loss. The results of the study were published in the English-language journal "Obesity".

Weight loss through behavioral therapy in primary medical facilities

Intensive behavioral therapy in combination with liraglutide 3.0 mg (Saxenda) can lead to clinically meaningful weight loss in people who receive such a form of treatment in primary medical facilities, reports the research team. Liraglutide 3.0 mg was originally developed to treat diabetes.

The results were impressive

In the current study, the effectiveness of intensive behavioral therapy with liraglutide 3.0 mg was examined. For the short, short 15-minute consultation, the results are impressive, especially considering the fact that participants were treated in a primary care facility without being enrolled in a weight loss group program at an academic medical center or other The researchers had to register the facility.

How did the study work?

The 282 adult participants with obesity were enrolled in 17 primary care clinics in the United States. All participants took part in 23 one-on-one consultations, which only lasted 15 minutes. These talks spanned 56 weeks. The sessions were conducted by registered nutritionists following a detailed treatment protocol.

How much did the participants lose?

After the first 28 weeks, those receiving counseling plus placebo lost an average of 5.4 percent of their original body weight. In contrast, in people who received counseling sessions and liraglutide 3.0 mg, the weight loss was 8.4 percent. Overall, 44.3 percent and 69 percent of these participants lost five percent or more of their original body weight, which is a common criterion for clinically meaningful weight loss.

Differences in weight loss were clearly evident

At week 56, both groups had regained a small amount of weight (from week 28), so the mean weight loss for intensive behavioral therapy plus placebo was four percent, compared to 7.4 percent for those who underwent intensive behavioral therapy and liraglutide 3, 0 mg received. This means that 38.8 percent and 61.5 percent of these participants lost more than or exactly five percent of their starting weight.

Weight Loss Benefits

These two treatment approaches, intensive behavioral therapy and medication, seem to have complementary mechanisms of action. Weight loss in both treatment groups was associated with an improvement in quality of life and measured cardiometabolic risk factors such as waist circumference, triglyceride levels and hemoglobin A1c (a measure of blood sugar control).

Who can carry out such treatment?

The positive results in terms of weight loss indicate that the group of people who are likely to be given such treatment should be expanded. Currently, only medical personnel such as doctors or nurses can carry them out. Registered dietitians and other professionals may only perform such combined treatment under the supervision of a primary care provider, such as a medical professional who must be physically present during on-site treatment. (As)

Author and source information

This text corresponds to the specifications of the medical literature, medical guidelines and current studies and has been checked by medical doctors.

Swell:

  • Thomas A. Wadden, Jena Shaw Tronieri, Danny Sugimoto, Michael Taulo Lund, Pernille Auerbach et al .: Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial, in Obesity (Published Feb. 24 .2020), Obesity


Video: Metabolic Syndrome: A Dangerous Combination of Risk Factors (September 2022).


Comments:

  1. Gror

    I think you are making a mistake. I can prove it. Email me at PM, we will talk.

  2. Milrajas

    I can offer you visit the site, with a huge number of articles on the topic that interests you.

  3. Macray

    I fully share your opinion. There is something in this and I think this is a good idea. I agree with you.

  4. Mikakora

    great



Write a message